Your finger accessory just got a federal stamp, and it’s not the kind you get at a concert. RingConn’s parent company says the FDA has granted 510(k) clearance for blood oxygen monitoring on the RingConn Smart Ring.
Shenzhen Ninenovo Technology Limited announced the news on Oct. 10, according to its press release on PR Newswire. The company lists the clearance number as K260490.
What the RingConn smart ring clearance actually means
Here’s the fine print, because it matters. A 510(k) clearance is not an FDA “approval.” Instead, it means the agency found a device “substantially equivalent” to products already legally on the market. The company says that is what happened here, as republished in The Manila Times.
The clearance covers non-invasive SpO2 measurement. That is the percentage of oxygen your blood is carrying. The ring reads it with PPG sensor technology, which uses light to detect changes in blood flow at your finger.
It does not cover everything the ring does, though. A third-party explainer describes RingConn’s blood pressure feature as a wellness tool, not an FDA-cleared one. That source is low-authority, so treat it as unconfirmed. Separately, one tech outlet describes the ring’s sleep apnea screening as not FDA-cleared.
Why the clearance matters to the RingConn ring
For a wearable, a clearance is a credibility upgrade. Anyone can print “blood oxygen” on a box. A federal review is a different kind of proof, and this one comes from regulators.
RingConn says the clearance gives it compliance assurance as it expands into the U.S. healthcare and wellness market. The company also says it sells in more than 190 countries and regions. It holds certifications in the EU, U.S., Japan, UK and Australia.
The pitch has always been simple: a RingConn smart ring with no subscription. The Gen 3 launched globally on May 29, 2026, starting at $349, according to Memeburn. Add a federal clearance, and that pitch gets harder for rivals to wave away. Meanwhile, competitors are chasing other angles, as in Circular’s new rings with contactless payments and vibrating alerts.
What we still don’t know about the FDA-cleared smart ring
So what’s missing? Quite a bit.
The release does not name the specific model covered. It does not name the predicate device. It also does not spell out the intended-use limits, such as overnight tracking versus spot checks.
Whether this is RingConn’s first clearance is also murky. Some reviews call the earlier Gen 2’s SpO2 feature FDA cleared. Others suggest RingConn lacks FDA-cleared diagnostics. Because those accounts don’t agree, we are not calling this a first.
We also have not independently confirmed the 510(k) number against the FDA’s public database. Every account we found traces back to the same company release. That includes the lightly reworked versions on smaller news sites (a lot of copy-paste out there).
Here’s the thing for your wrist
If you wear a RingConn smart ring or any rival, don’t treat it as a diagnosis tool. These devices are built for trends, like how your nights are going and whether your numbers drift. Low readings, or symptoms like shortness of breath, belong with a doctor. They do not belong in an app. For a sense of how wearable and health research can move, see this look at brain blood flow in high-risk adults.
The next steps are straightforward. The FDA’s 510(k) database should post the details with a lag. RingConn can clear up which models are covered and how the feature reaches users. The company also says it is continuing clinical research on blood oxygen monitoring to build a data foundation for validation.
For now, the clearance is real on paper and thin on detail. The ring has its federal seal. The fine print is still on its way.
